vs
Side-by-side financial comparison of Fresenius Medical Care AG (FMS) and MANGOCEUTICALS, INC. (MGRX). Click either name above to swap in a different company.
Fresenius Medical Care AG is the larger business by last-quarter revenue ($5.5B vs $94.4K, roughly 58024.1× MANGOCEUTICALS, INC.). Fresenius Medical Care AG runs the higher net margin — 7.9% vs -2935.1%, a 2943.0% gap on every dollar of revenue. On growth, Fresenius Medical Care AG posted the faster year-over-year revenue change (-0.3% vs -10.3%).
Fresenius Medical Care AG & Co. KGaA is a German healthcare company which provides kidney dialysis services through a network of 4,171 outpatient dialysis centers, serving 345,425 patients. The company primarily treats end-stage renal disease (ESRD), which requires patients to undergo dialysis 3 times per week for the rest of their lives.
MANGOCEUTICALS, INC. is a men's health and personal care company that develops, manufactures, and distributes science-backed consumer products, including dietary supplements, skincare, and hair care solutions targeted at common male wellness needs. It mainly operates in the U.S. market, selling via direct-to-consumer e-commerce platforms and select retail partners, prioritizing accessible, transparent wellness offerings for adult male consumers.
FMS vs MGRX — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $5.5B | $94.4K |
| Net Profit | $434.2M | $-2.8M |
| Gross Margin | 27.4% | 50.3% |
| Operating Margin | 11.7% | -389.7% |
| Net Margin | 7.9% | -2935.1% |
| Revenue YoY | -0.3% | -10.3% |
| Net Profit YoY | 240.4% | -42.1% |
| EPS (diluted) | — | $0.38 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $5.5B | $94.4K | ||
| Q3 25 | — | $84.2K | ||
| Q2 25 | — | $168.1K | ||
| Q1 25 | — | $109.3K | ||
| Q4 24 | $5.5B | $105.2K | ||
| Q3 24 | — | $133.4K | ||
| Q2 24 | — | $163.2K | ||
| Q1 24 | — | $214.1K |
| Q4 25 | $434.2M | $-2.8M | ||
| Q3 25 | — | $-7.6M | ||
| Q2 25 | — | $-5.4M | ||
| Q1 25 | — | $-4.8M | ||
| Q4 24 | $127.6M | $-1.9M | ||
| Q3 24 | — | $-2.0M | ||
| Q2 24 | — | $-2.4M | ||
| Q1 24 | — | $-2.4M |
| Q4 25 | 27.4% | 50.3% | ||
| Q3 25 | — | 60.4% | ||
| Q2 25 | — | 53.5% | ||
| Q1 25 | — | 56.8% | ||
| Q4 24 | 25.0% | 76.1% | ||
| Q3 24 | — | 62.0% | ||
| Q2 24 | — | 42.8% | ||
| Q1 24 | — | 68.8% |
| Q4 25 | 11.7% | -389.7% | ||
| Q3 25 | — | -8953.5% | ||
| Q2 25 | — | -3134.0% | ||
| Q1 25 | — | -4440.0% | ||
| Q4 24 | 5.1% | -1594.0% | ||
| Q3 24 | — | -1318.2% | ||
| Q2 24 | — | -1329.1% | ||
| Q1 24 | — | -1105.9% |
| Q4 25 | 7.9% | -2935.1% | ||
| Q3 25 | — | -9042.8% | ||
| Q2 25 | — | -3221.6% | ||
| Q1 25 | — | -4427.4% | ||
| Q4 24 | 2.3% | -1851.2% | ||
| Q3 24 | — | -1499.0% | ||
| Q2 24 | — | -1465.4% | ||
| Q1 24 | — | -1105.9% |
| Q4 25 | — | $0.38 | ||
| Q3 25 | — | $-0.69 | ||
| Q2 25 | — | $-0.57 | ||
| Q1 25 | — | $-1.29 | ||
| Q4 24 | — | $-0.79 | ||
| Q3 24 | — | $-1.14 | ||
| Q2 24 | — | $-1.37 | ||
| Q1 24 | — | $-1.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.7B | $1.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $15.4B | $15.2M |
| Total Assets | $33.5B | $16.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.7B | $1.5M | ||
| Q3 25 | — | $481.3K | ||
| Q2 25 | — | $101.0K | ||
| Q1 25 | — | $76.5K | ||
| Q4 24 | $1.3B | $58.7K | ||
| Q3 24 | — | $73.9K | ||
| Q2 24 | — | $490.2K | ||
| Q1 24 | — | $15.3K |
| Q4 25 | $15.4B | $15.2M | ||
| Q3 25 | — | $15.7M | ||
| Q2 25 | — | $19.2M | ||
| Q1 25 | — | $20.3M | ||
| Q4 24 | $17.0B | $13.9M | ||
| Q3 24 | — | $13.4M | ||
| Q2 24 | — | $13.8M | ||
| Q1 24 | — | $-958.4K |
| Q4 25 | $33.5B | $16.1M | ||
| Q3 25 | — | $16.5M | ||
| Q2 25 | — | $20.8M | ||
| Q1 25 | — | $21.8M | ||
| Q4 24 | $36.3B | $15.4M | ||
| Q3 24 | — | $14.8M | ||
| Q2 24 | — | $15.2M | ||
| Q1 24 | — | $301.4K |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.9B | $-1.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 6.67× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.9B | $-1.1M | ||
| Q3 25 | — | $-1.2M | ||
| Q2 25 | — | $-1.3M | ||
| Q1 25 | — | $-2.3M | ||
| Q4 24 | $2.6B | $-1.1M | ||
| Q3 24 | — | $-1.2M | ||
| Q2 24 | — | $-1.6M | ||
| Q1 24 | — | $-991.1K |
| Q4 25 | 6.67× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 20.20× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
